{"id":"W2966944913","doi":"10.1200/jco.2009.27.15_suppl.3552","title":"Dual epidermal growth factor receptor (EGFR) inhibition: Phase I study combining cetuximab (C225) and erlotinib (E) in advanced solid tumors","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cetuximab; Medicine; Erlotinib; Rash; Mucositis; Epidermal growth factor receptor; Internal medicine; Neutropenia; Toxicity; Pharmacology; Oncology; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008503376,0.001440226,0.001548293,0.0004460134,0.0003174322,0.0008770082,0.0007587351,0.001022271,0.001580729],"category_scores_gemma":[0.0003302764,0.0005145484,0.000814792,0.0003759488,0.0007229766,0.0005585941,0.0003432003,0.001906402,0.0005045721],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009741984,"about_ca_system_score_gemma":0.001427837,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001419717,"about_ca_topic_score_gemma":0.003038212,"domain_scores_codex":[0.9997926,0.00006670542,0.00001350731,0.00003779103,0.00002845028,0.00006097555],"domain_scores_gemma":[0.9997097,0.00003327006,0.00004000388,0.00001735229,0.00001682649,0.0001827987],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4419297,0.1669374,0.01118242,0.00187004,0.001953492,0.001261442,0.0005341566,0.01013118,0.2167041,0.0005822219,0.00508501,0.1418289],"study_design_scores_gemma":[0.3098716,0.6483842,0.01614641,0.00006322496,0.0006391373,0.0007889543,0.00009530709,0.003826803,0.0166913,0.0001559275,0.003290931,0.00004628809],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996604,0.0009486091,0.0003187454,0.0001248783,0.00003637693,0.0008800077,0.0002432294,0.00004209684,0.0008022108],"genre_scores_gemma":[0.9946905,0.001197902,0.0008907754,0.0003164974,0.00005795661,0.0007201205,0.000829245,0.00001044089,0.001286393],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001580729,"threshold_uncertainty_score":0.007068276,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08132331328723262,"score_gpt":0.5071893561485397,"score_spread":0.425866042861307,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}